Azurity Pharmaceuticals Receives FDA Approval for Ferabright™, the First Iron-Based MRI Contrast Agent for Brain Tumour Imaging

Azurity Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved FerabrightTM (ferumoxytol injection), the first and...

October 20, 2025 | Monday | News
Corventum Secures FDA Clearance for IND of CVT-130 to Prevent Chemotherapy-Induced Cardiotoxicity

-Corventum, Inc., a new medicines company advancing novel therapies to make existing cancer treatments safer and more effective,  announced the clea...

October 15, 2025 | Wednesday | News
IDT and Hamilton Partner to Automate Next-Generation Sequencing Workflows for Global Genomic Research

To equip users with a complete next generation sequencing (NGS) solution from sample to answer, global genomics leader Integrated DNA Technologies (IDT),...

October 14, 2025 | Tuesday | News
Excellergy Launches with $70M Series A to Redefine Allergy Treatment with First-in-Class Trifunctional ECRIs

-Redefining Allergy Treatment with New Class of Trifunctional ECRIs designed to deliver powerful efficacy, rapid relief and complete control of alle...

October 14, 2025 | Tuesday | News
Gelteq Partners with Melbourne Health to Develop Innovative Oral Gel Product for Bowel Polyp Prevention

Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solution...

October 10, 2025 | Friday | News
MannKind Completes Acquisition of scPharmaceuticals to Strengthen Cardiometabolic Portfolio and Accelerate Growth

MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPhar...

October 08, 2025 | Wednesday | News
Philips Unveils Next-Generation CT and Helium-Free MR Systems to Transform Precision and Sustainability in Radiation Therapy

New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term value Philips deb...

September 29, 2025 | Monday | News
Eisai and Biogen Gain Australian Approval for LEQEMBI® in Early Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. announced that the Therapeutic Goods Administration (TGA) of Australia has approved LEQEMBI® (lecanemab), a humanized...

September 25, 2025 | Thursday | News
Ncardia Launches First iPSC-Derived Non-Human Primate Cardiomyocytes for Translational Cardiac Research

-Ncardia, a leader in stem cell–based solutions for drug discovery and safety assessment,  announced the launch of Ncyte® NHP-C vCardiomyo...

September 24, 2025 | Wednesday | News
Alvotech and Fuji Pharma Secure Japanese Approval for Three New Biosimilars: Denosumab, Golimumab, and Aflibercept

Alvotech a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced th...

September 22, 2025 | Monday | News
AccuStem Sciences and EmeritusDX Expand Blood-Based Cancer Testing Capabilities with Advanced miRNA Platform

AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, annou...

September 18, 2025 | Thursday | News
Galimedix Completes Phase 1 Trial of Oral GAL-101, Advancing Toward Phase 2 in Alzheimer’s Disease

GAL-101 was well tolerated; excellent safety and pharmacokinetic profile strongly support oral administration GAL-101 effectively crosses the blood-br...

September 15, 2025 | Monday | News
AVITA Medical Secures CE Mark for RECELL® GO, Expanding European Access to Innovative Burn Care

- AVITA Medical, Inc., a leading therapeutic acute wound care company,announced it has received the CE Mark under the European Union Medical Device Regul...

September 15, 2025 | Monday | News
uLab Systems and Biolux Technology Forge Strategic Partnership to Redefine Clear Aligner Therapy

uLab Systems®, a leader in digital orthodontic innovation, and Biolux Technology, creator of the OrthoPulse® near-infrared (NIR) light therapy de...

September 12, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close